Rosiglitazone Evaluated for Cardiac Outcomes and Regulation of Glycaemia in Diabetes (RECORD): Study design and protocol

Diabetologia

Volumn 48, Issue 9, 2005, Pages 1726-1735

  Home, P D ^a,b   Pocock, S J ^c   Beck Nielsen, H ^d   Gomis, R ^e   Hanefeld, M ^f   Dargie, H ^g   Komajda, M ^h   Gubb, J ⁱ   Biswas, N ^j   Jones, N P ⁱ  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

^b Newcastle Diabetes Centre   (United Kingdom)

^c LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^d ODENSE UNIVERSITY HOSPITAL   (Denmark)

^e HOSPITAL CLÍNIC   (Spain)

^f DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^g UNIVERSITY OF GLASGOW   (United Kingdom)

^h PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

ⁱ GLAXOSMITHKLINE   (United Kingdom)

^j GLAXOSMITHKLINE   (United States)

more..

Author keywords

Cardiovascular outcomes; RECORD study; Rosiglitazone; Thiazolidinediones; Type 2 diabetes

Indexed keywords

ALANINE AMINOTRANSFERASE; GLIBENCLAMIDE; GLICLAZIDE; GLIMEPIRIDE; GLUCOSE; HEMOGLOBIN A1C; METFORMIN; ROSIGLITAZONE; SULFONYLUREA DERIVATIVE;

ABDOMINAL PAIN; ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; ADULT; AGED; ANOREXIA; ARTICLE; AUSTRALIA AND NEW ZEALAND; CARDIOVASCULAR DISEASE; CAUCASIAN; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEATH; DISEASE COURSE; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; EUROPE; FATIGUE; FEMALE; GLUCOSE BLOOD LEVEL; HOSPITALIZATION; HUMAN; INFORMATION PROCESSING; LIVER DYSFUNCTION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; TITRIMETRY; TREATMENT OUTCOME; URINE COLOR; VOMITING;

BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; MALE; METFORMIN; SAFETY; SULFONYLUREA COMPOUNDS; THIAZOLIDINEDIONES;

EID: 24944569269     PISSN: 0012186X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00125-005-1869-1     Document Type: Article

References (36)

1. Wei M, Gaskill SP, Haffner SM, Stern MP (1998) Effects of diabetes and level of glycemia on all-cause and cardiovascular mortality. The San Antonio Heart Study. Diabetes Care 21:771167-1172
2. Morrish NJ, Wang S-L, Stevens LK, Fuller JH, Keen H and the WHO Multinational Study Group (2001) Mortality and causes of death in the WHO Multinational Study of Vascular Disease in Diabetes. Diabetologia 44(Suppl 2):S14-S21
3. Reaven GM (1988) Banting lecture: role of insulin resistance in human disease. Diabetes 37:1595-1607
4. Haffner SM, Valdez RA, Hazuda HP et al (1992) Prospective analysis of the insulin-resistance syndrome (syndrome X). Diabetes 41:715-722
5. Mayerson AB, Hundal RS, Dufour S et al (2002) The effects of rosiglitazone on insulin sensitivity, lipolysis, and hepatic and skeletal muscle triglyceride content in patients with Type 2 diabetes. Diabetes 51:797-802
6. Miyazaki Y, Glass L, Triplitt C et al (2001) Effect of rosiglitazone on glucose and non-esterified fatty acid metabolism in Type II diabetic patients. Diabetologia 44:2210-2219
7. Carey DG, Cowin GJ, Galloway GJ et al (2002) Effect of rosiglitazone on insulin sensitivity and body composition in type 2 diabetic patients. Obes Res 10:1008-1015
8. Lebovitz HE, Dole JF, Patwardhan R, Rappaport EB, Freed MI (2001) Rosiglitazone monotherapy is effective in patients with Type 2 diabetes. J Clin Endocrinol Metab 86:280-288
9. Hällsten K, Virtanen KA, Lönnqvist F et al (2002) Rosiglitazone but not metformin enhances insulin- and exercise-stimulated skeletal muscle glucose uptake in patients with newly diagnosed type 2 diabetes. Diabetes 51:3479-3485
10. Aronoff S, Rosenblatt S, Braithwaite S et al (2000) Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes. Diabetes Care 23: 1605-1611
11. Miyazaki Y, Mahankali A, Matsuda M et al (2001) Improved glycemic control and enhanced insulin sensitivity in type 2 diabetic subject treated with pioglitazone. Diabetes Care 24:710-719
12. Bakris G, Viberti G, Weston WM, Heise M, Porter LE, Freed MI (2003) Rosiglitazone reduces urinary albumin excretion in type II diabetes. J Hum Hypertens 17:7-12
13. Raji A, Seely EW, Bekins SA, Williams GH, Simonson DC (2003) Rosiglitazone improves insulin sensitivity and lowers blood pressure in hypertensive patients. Diabetes Care 26:172-178
14. Haffner SM, Greenberg AS, Weston WM, Chen H, Williams K, Freed MI (2002) Effect of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with Type 2 diabetes mellitus. Circulation 106:679-684
15. Freed MI, Ratner R, Marcovina SM et al (2002) Effects of rosiglitazone alone and in combination with atorvastatin on the metabolic abnormalities in Type 2 diabetes mellitus. Am J Cardiol 90:947-952
16. Ovalle F, Bell DS (2002) Effect of thiazolidinediones on high-density lipoprotein subfractions. Endocr Pract 8:102-104
17. Cheng-Lai A, Levine A (2000) Rosiglitazone: an agent from the thiazolidinedione class for the treatment of Type 2 diabetes. Heart Dis 2:326-333
18. Nesto RW, Bell D, Bonow RO et al (2003) Thiazolidinedione use, fluid retention, and congestive heart failure. A consensus statement from the American Heart Association and American Diabetes Association. Circulation 108:2941-2948
19. Tang WHW, Francis GS, Hoogwerf BH, Young JB (2003) Fluid retention after initiation of thiazolidinedione therapy in diabetic patients with established chronic heart failure. J Am Coll Cardiol 41:1394-1398
20. King AB (2000) A comparison in a clinical setting of the efficacy and side effects of three thiazolidinediones. Diabetes Care 23:557
21. Lebovitz HE, Kreider M, Freed MI (2002) Evaluation of liver function in type 2 diabetic patients during clinical trials: evidence that rosiglitazone does not cause hepatic dysfunction. Diabetes Care 25:815-821
22. Chilcott J, Tappenden P, Jones ML, Wight JP (2001) A systematic review of the clinical effectiveness of pioglitazone treatment of type 2 diabetes mellitus. Clin Ther 23:1792-1823
23. UK Prospective Diabetes Study (UKPDS) Group (1998) Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352:837-853
24. UK Prospective Diabetes Study (UKPDS) Group (1998) Effect of intensive blood-glucose control with metformin on complications in overweight patients with Type 2 diabetes (UKPDS 34). Lancet 352:854-865
25. World Medical Association (1997) Declaration of Helsinki. Recommendations guiding physicians in biomedical research involving human subjects. JAMA 277:925-926
26. Grootenhuis PA, Snoek FJ, Heine RJ, Bouter LM (1994) Development of a Type 2 diabetes symptom checklist: a measure of symptom severity. Diabet Med 11:253-261
27. Drummond MF, O'Brien B, Stoddart GL, Torrance GW (eds) (1997) Methods for the Economic Evaluation of Health Care Programmes, 2nd edn. Oxford University Press, New York
28. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC (1985) Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28:412-419
29. Jennison C, Turnbull BW (2000) Group Sequential Methods with Application to Clinical Trials, Chapman and Hall/CRC, Boca Raton (Section 2.7.2)
30. Goldberg RB, Mellies MJ, Sacks FM et al (1998) Cardiovascular events and their reduction with pravastatin in diabetic and glucose-intolerant myocardial infarction survivors with average cholesterol levels: subgroup analyses in the Cholesterol And Recurrent Events (CARE) trial. Circulation 98:2513-2519
31. Heart Outcomes Prevention Evaluation (HOPE) Study Investigators (2000) Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet 355:253-259
32. Home PD, Pocock S, Beck-Nielsen H et al (2004) Rosiglitazone evaluated for cardiac outcomes and regulation of glycaemia in diabetes (RECORD): an interim analysis of glycaemia at 18 months. Diabetologia 47(Suppl 1):A262 (Abstract no. 725)
33. Oshinyemi K, Garcia S, Curtis P, Zambanini A, Stewart M (2004) Evaluation of the effects of rosiglitazone combination therapy on ambulatory blood pressure after 6 months; a 12 month sub-study of the RECORD trial in people with Type 2 diabetes mellitus. Diabetologia 47(Suppl 1):A262 (Abstract no. 724)
34. Haffner SM, Lehto S, Rönnemaa T, Pyörälä K, Laakso M (1998) Mortality from coronary heart disease in subjects with Type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 339:229-234
35. European Diabetes Policy Group 1999 (1999) A desktop guide to Type 2 diabetes mellitus. Diabet Med 16:716-730
36. Sheen AJ (2001) Hepatotoxicity with thiazolidinediones: is it a class effect? Drug Saf 24:873-888